Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 May 2024
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA968)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 April 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2024
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 March 2024
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2024
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) (TA936)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 November 2023
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) (TA933)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2023
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) (TA932)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 November 2023
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 November 2023
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments [ID6193]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 8 May 2024
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 May 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 June 2024
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 June 2024
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 August 2024
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [ID4042]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Isatuximab in combination for newly diagnosed multiple myeloma [ID3981]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
High intensity focused ultrasound ablation for pain caused by bone metastasesStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment TS ID 11963Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405Status:In development | In consultationProgramme:Health technology evaluationConsultation end date: 23 May 2024Expected publication date: TBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma TS ID 11987Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments TSID 11915Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years TSID 11982Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments TSID 11969Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC